{"id":137565,"date":"2026-09-28T14:10:48","date_gmt":"2026-09-28T14:10:48","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/137565\/"},"modified":"2026-09-28T14:10:48","modified_gmt":"2026-09-28T14:10:48","slug":"novartis-stock-drops-as-trial-failures-ripple-across-biotech-partners-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/137565\/","title":{"rendered":"Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">On Tuesday, Novartis AG <a href=\"https:\/\/finance.yahoo.com\/quote\/NVS\/\" data-ylk=\"slk:(NYSE%3A;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;(NYSE:&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" class=\"ticker-link\" rel=\"nofollow noopener\">(NYSE:<\/a><a href=\"https:\/\/finance.yahoo.com\/quote\/NVS\/\" data-ylk=\"slk:NVS;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NVS&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" class=\"ticker\" rel=\"nofollow noopener\">NVS<\/a>) stock witnessed one of the sharpest single-day declines for the company in recent history.  <\/p>\n<p>        Phase 3 HARBOR Trial Misses Primary Endpoint          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">On Tuesday, the company shared <a href=\"https:\/\/www.novartis.com\/news\/media-releases\/novartis-provides-update-delpacibart-etedesiran-del-desiran-phase-iii-harbor-study-treatment-myotonic-dystrophy-type-1-dm1\" data-ylk=\"slk:data;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;data&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">data<\/a> from the global Phase 3 HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM1).  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The study did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Read Also:<a href=\"https:\/\/www.benzinga.com\/markets\/biotech\/26\/09\/61632551\/novartis-bristol-myers-put-autoimmune-car-t-trials-on-ice-as-safety-fears-explode?nid=61654807&amp;utm_campaign=partner_feed&amp;utm_medium=partner_feed&amp;utm_source=yahooFinance\" data-ylk=\"slk:A%20Wall%20Street%20Analyst%20Spotted%20the%20Trial%20Freeze%E2%80%94Then%20Came%20News%20of%20Three%20Deaths;elm:affiliate_link;itc:0;sec:content-canvas;elmt:premonetized;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;A Wall Street Analyst Spotted the Trial Freeze\u2014Then Came News of Three Deaths&quot;,&quot;yLinkElement&quot;:&quot;affiliate_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkElementType&quot;:&quot;premonetized&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;,&quot;yHasCommerce&quot;:true,&quot;yAffiliateService&quot;:&quot;premonetized&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">A Wall Street Analyst Spotted the Trial Freeze\u2014Then Came News of Three Deaths<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Myotonia is a neuromuscular condition where muscles are unable to relax right away after a voluntary contraction or strong effort.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Safety findings from HARBOR were generally consistent with previously reported data.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis is evaluating the full HARBOR dataset and will engage with health authorities to determine the most appropriate development path for del-desiran.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Del-desiran is one of three antibody-oligonucleotide conjugate (AOC) therapies added to the Novartis neuromuscular pipeline through the acquisition of Avidity Biosciences <a href=\"https:\/\/www.benzinga.com\/m-a\/25\/10\/48427774\/avidity-shareholders-win-big-as-novartis-moves-fast-on-12-billion-deal?nid=61654807&amp;utm_campaign=partner_feed&amp;utm_medium=partner_feed&amp;utm_source=yahooFinance\" data-ylk=\"slk:for%20a%20whopping%20%2412%20billion;elm:affiliate_link;itc:0;sec:content-canvas;elmt:premonetized;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;for a whopping $12 billion&quot;,&quot;yLinkElement&quot;:&quot;affiliate_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkElementType&quot;:&quot;premonetized&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;,&quot;yHasCommerce&quot;:true,&quot;yAffiliateService&quot;:&quot;premonetized&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">for a whopping $12 billion<\/a>.  <\/p>\n<p>        Status of $12 Billion Avidity Pipeline Acquisition          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis is advancing delpacibart zotadirsen (del-zota) in patients with Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44).  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The company filed del-zota for accelerated approval and received FDA priority review designation.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis is planning to meet with the FDA on next steps for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) based on <a href=\"https:\/\/www.benzinga.com\/news\/health-care\/26\/06\/53139718\/novartis-12-billion-bet-pays-off-with-encouraging-data-from-rare-neuromuscular-disease-study?nid=61654807&amp;utm_campaign=partner_feed&amp;utm_medium=partner_feed&amp;utm_source=yahooFinance\" data-ylk=\"slk:recent%20positive%20Phase%201%2F2%20biomarker%20data;elm:affiliate_link;itc:0;sec:content-canvas;elmt:premonetized;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;recent positive Phase 1\/2 biomarker data&quot;,&quot;yLinkElement&quot;:&quot;affiliate_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkElementType&quot;:&quot;premonetized&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;,&quot;yHasCommerce&quot;:true,&quot;yAffiliateService&quot;:&quot;premonetized&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">recent positive Phase 1\/2 biomarker data<\/a>.  <\/p>\n<p>        Pelacarsen Cardiovascular Trial Fails          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">On Friday, Novartis also shared another trial disappointment after it released data from the pelacarsen phase 3 Lp(a)HORIZON trial, a cardiovascular outcomes study.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The study did <a href=\"https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd\" data-ylk=\"slk:not;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;not&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">not<\/a> meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Lower lipoprotein (a) (Lp(a)) levels were achieved with pelacarsen in this study population, which was receiving guideline-directed treatments, including lipid-lowering and antihypertensive therapies.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Elevated Lp(a) is an inherited cardiovascular risk factor affecting approximately one in five people worldwide with no approved targeted treatment.  <\/p>\n<p>            Ripple Effect Hits Partners           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">After the update, Ionis Pharmaceuticals Inc. <a href=\"https:\/\/finance.yahoo.com\/quote\/IONS\/\" data-ylk=\"slk:(NASDAQ%3A;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;(NASDAQ:&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" class=\"ticker-link\" rel=\"nofollow noopener\">(NASDAQ:<\/a><a href=\"https:\/\/finance.yahoo.com\/quote\/IONS\/\" data-ylk=\"slk:IONS;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;IONS&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" class=\"ticker\" rel=\"nofollow noopener\">IONS<\/a>) stock also tanked as Novartis obtained global rights to develop, manufacture, and commercialize pelacarsen under a <a href=\"https:\/\/www.benzinga.com\/pressreleases\/26\/09\/b61641206\/ionis-partner-novartis-announces-lp-horizon-phase-3-topline-results-pelacarsen-patients-elevated-lp-?nid=61654807&amp;utm_campaign=partner_feed&amp;utm_medium=partner_feed&amp;utm_source=yahooFinance\" data-ylk=\"slk:2019%20license%20and%20collaboration%20agreement;elm:affiliate_link;itc:0;sec:content-canvas;elmt:premonetized;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;2019 license and collaboration agreement&quot;,&quot;yLinkElement&quot;:&quot;affiliate_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkElementType&quot;:&quot;premonetized&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;,&quot;yHasCommerce&quot;:true,&quot;yAffiliateService&quot;:&quot;premonetized&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">2019 license and collaboration agreement<\/a>.  <\/p>\n","protected":false},"excerpt":{"rendered":"On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent&hellip;\n","protected":false},"author":2,"featured_media":137566,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[28644,66339,206,1078,6650,66338],"class_list":["post-137565","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-duchenne-muscular-dystrophy","tag-neuromuscular-condition","tag-novartis","tag-novartis-ag","tag-primary-endpoint","tag-reported-data"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117349071700047145","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/137565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=137565"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/137565\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/137566"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=137565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=137565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=137565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}